Adalimumab (brand name HUMIRA ) is the third TNF inhibitor , after infliximab and etanercept , to be approved in the United States . Like infliximab and etanercept, adalimumab binds to TNF? , preventing it from activating TNF receptors; adalimumab was constructed from a fully human monoclonal antibody , while infliximab is a mouse -human chimeric antibody and etanercept is a TNF receptor-IgG fusion protein . よりたくさんの

Adalimumab (brand name HUMIRA ) is the third TNF inhibitor , after infliximab and etanercept , to be approved in the United States . Like infliximab and etanercept, adalimumab binds to TNF? , preventing it from activating TNF receptors; adalimumab was constructed from a fully human monoclonal antibody , while infliximab is a mouse -human chimeric antibody and etanercept is a TNF receptor-IgG fusion protein . TNF? inactivation has proven to be important in downregulating the inflammatory reactions associated with autoimmune diseases . As of 2008 adalimumab has been approved by the FDA for the treatment of rheumatoid arthritis , psoriatic arthritis , ankylosing spondylitis , Crohn's disease , moderate to severe chronic psoriasis and juvenile idiopathic arthritis . less